Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

Br J Haematol. 2021 Jan;192(1):e28-e31. doi: 10.1111/bjh.17177. Epub 2020 Oct 31.
No abstract available

Keywords: multicentric Castleman disease; siltuximab.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Castleman Disease / diagnosis
  • Castleman Disease / drug therapy*
  • Humans
  • Placebo Effect
  • Proportional Hazards Models
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • siltuximab

Supplementary concepts

  • Multi-centric Castleman's Disease